TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05786950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: compound ipratropium bromide solution (3mg salbutamol and 500μg ipratropium, Boehringer Ingelheim Limited, Germany)
Description: inhaled compound ipratropium bromide solution (3mg salbutamol and 500μg ipratropium, Boehringer Ingelheim Limited, Germany)
Study: NCT06043505

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Echographic hemodynamic algorithm guiding fluid resuscitation
Description: Ultrasound Hemodynamic Algorithm (UHA):~1. st step: 1/ Assessment of left ventricular filling pressures by Mitral Doppler echocardiography (2) 2/ Pulmonary ultrasound on 4 anterior dials (3)~   E/Ea \>14 and/or E/A \>2~  * YES =\> No filling test =\> Bilateral anterior B lines on lung ultrasound =\> YES =\> Consider administration of diuretics~  * NO =\> Step 2~2. nd step: Assessment of filling response by dynamic maneuvers VTI (Velocity Time Integral) increase \>15% after passive leg raising (4) or Mini-fluid challenge (5,6) Or decision of a 250ml filling test~   * YES =\> consider 250ml bolus filling~  * NO =\> stop vascular filling~3. rd step if dynamic maneuvers in favor of a response to filling: 1/ Assessment of response to 250ml filling 2/ If no response to vascular filling: Pulmonary ultrasound on 4 anterior dials (3) Change from a pulmonary profile A to a pulmonary profile B~   * YES =\> depletion~  * NO =\> stop vascular filling
Study: NCT05234905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human adenovirus type 5＋Camrelizumab
Description: Recombinant human adenovirus type 5: one lesion was selected for intratumoral injection.Intratumoral injection of H101 was performed on day 1 and day 4 of each cycle, and was repeated once every 3 weeks. H101 dose:~① Tumor maximum diameter ≤5cm, 1.5×1012vp (3 injections) on day 1, 1.0×1012vp (2 injections) on day 4.~② Tumor maximum diameter \>5cm but ≤10cm, 3.0×1012vp (6 injections) on day 1 and 2.0×1012vp (4 injections) on day 4.~③ Tumor maximum diameter \>10cm, 4.5×1012vp (9 injections) on day 1 and 3.0×1012vp (6 injections) on day 4.~H101 intratumoral injection until the tumor is completely regressed to stop the drug, but not more than 5 cycles at most.~Camrelizumab: administered after H101 on day 1 of each cycle and repeated for 3 weeks. Camrelizumab dose: 200 mg IV.
Study: NCT06343766

Intervention type: GENETIC
Intervention: DNA collation and genotyping
Description: DNA collation and genotyping of specific genes ENAM rs3796703, AMBN rs4694075), TUFT1 rs78802584 and KLK4 rs2242670 through PCR and sequencing for various SNPs~Dental examinations by comparing dental covariates such as the number of DMF-T index, presence of biofilm, gingivitis, fluorosis, and detection of interproximal caries with caries progression.

Intervention type: GENETIC
Intervention: DNA collation and genotyping
Description: DNA collation and genotyping of specific genes ENAM rs3796703, AMBN rs4694075), TUFT1 rs78802584 and KLK4 rs2242670 through PCR and sequencing for various SNPs~Dental examinations by comparing dental covariates such as the number of DMF-T index, presence of biofilm, gingivitis, fluorosis, and detection of interproximal caries with caries progression.
Study: NCT06477887

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Dentin Matrix
Description: Steps of Allogenic Dentin Processing:~Wash with distilled water for 30-120 minutes. Ultrasonic Cleaning Cycles: 1st with distilled water for 5-10 minutes, 2nd with 5-7% hydrogen peroxide for 10-30 minutes, then the 3rd with distilled water for 5-10 minutes at 60-80.~Defatting with Chloroform Methanol Solution 1:0.5 for 3-12 hours. Demineralization with 0.5N HCL for 10-60 min. Dehydration with Neutral Ethyl Alcohol for 30 minutes, then Defatting with Chloroform Methanol Solution 1:0.5 for 3-12 hours.~Wash with normal saline and freeze dry, then sterilise using ethylene oxide gas.~The extracted socket will be filled with allogenic dentin

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous Partially Demineralized Dentine Matrix
Description: The extracted tooth will be cleaned with a diamond bur under abundant irrigation with physiological water. All filling materials (gutta-percha, composite, luting cements, etc.) will be removed with the outmost care and under magnification.~Subsequently, the tooth will be cut into fragments (5 × 5 mm) and inserted into the milling device (Tooth Transformer, Milan, Italy). According to the manufacturer, a disposable box containing disposable liquid solutions will be inserted into the device to ensure the demineralization of the graft with 0.1 M hydrochloric acid, 10% hydrogen peroxide, and demineralized water as a wash.~After 25 minutes, particle graft biomaterials will be obtained. The particle size will range from 815 µm with peaks up to 1110 µm.~The socket will be filled with the graft.
Study: NCT06490484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149 20mg BID
Description: Drug: HSK16149 20mg BID HSK16149 20mg, orally twice a day; treatment period: 4 weeks fixed dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 150mg BID
Description: Drug: Pregabalin 150mg BID Pregabalin 150mg, orally twice a day; treatment period: 1 week titration and 3 weeks fixed dose.
Study: NCT06529107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intermittent catheterization protocol based on the best evidence
Description: A best evidence-based protocol for intermittent catheterization after radical cervical cancer surgery
Study: NCT06252597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education and training
Description: education and training at a regularly scheduled occupational therapy clinic visit will be performed with handouts, verbal education, hands-on training, and video training
Study: NCT06230848

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multisensory Early Oral Administration of Human Milk (M-MILK)
Description: M-MILK is implemented as droplets, at day 3 of life, after every hands-on care, and during the beginning of a full gavage feeding. The infant may be supportively positioned in bed, held skin-to-skin by caregiver, or held/cradled by nurse or caregiver. The nurse draws up 1 mL of milk into the 1-mL syringe from a prepared bottle or enteral feeding syringe. The nurse then proceeds to implement M-MILK while observing the infant's responses closely. The nurse talks to the infant with a soft calm voice while providing gentle touch throughout the intervention. The nurse begins M-MILK by first placing 1-2 drops of milk onto the infant's upper lip, allowing the infant to feel and smell the milk. The nurse gently strokes the infant's lips with a pacifier/swab or infant's fingers. M-MILK will be provided based on infants' responses and cues. M-MILK is concluded if the infant is no longer engaged or has finished the 1 mL of milk.
Study: NCT05137574

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Pulmonary Index (IPI) monitoring
Description: Integrated Pulmonary Index (IPI) monitor will be applied to the patients, to provide numerical data obtained from the measurements of end-tidal carbon dioxide, respiratory rate, oxygen saturation measured by pulse oximetry (SpO2), and pulse rate.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Pulmonary Index (IPI) monitoring
Description: Integrated Pulmonary Index (IPI) monitor will be applied to the patients, to provide numerical data obtained from the measurements of end-tidal carbon dioxide, respiratory rate, oxygen saturation measured by pulse oximetry (SpO2), and pulse rate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: ketamine
Study: NCT06294301

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LP-005 Dose 1 (Single)
Description: A single dose of LP-005 (Dose 1) was administered intravenously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LP-005 Dose 2 (Single)
Description: A single dose of LP-005 (Dose 2) was administered intravenously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LP-005 Dose 3 (Single)
Description: A single dose of LP-005 (Dose 3) was administered intravenously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LP-005 Dose 4 (Single)
Description: A single dose of LP-005 (Dose 4) was administered intravenously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LP-005 Dose 5 (Single)
Description: A single dose of LP-005 (Dose 5) was administered intravenously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LP-005 Dose 6 (Single)
Description: A single dose of LP-005 (Dose 6) was administered intravenously.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Single)
Description: A single dose of placebo was administered intravenously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LP-005 Dose 7 (Multiple)
Description: LP-005 (Dose 7) was administered multiple times intravenously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LP-005 Dose 8 (Multiple)
Description: LP-005 (Dose 8) was administered multiple times intravenously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LP-005 Dose 9 (Multiple)
Description: LP-005 (Dose 9) was administered multiple times intravenously.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Multiple)
Description: Placebo was administered multiple times intravenously.
Study: NCT05842928

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PARTNER intervention
Description: The PARTNER intervention includes the following components:~1. Education for health care professionals~   A) written manual on deprescribing PSA-PIM, which consists of brief information and more detailed explanations;~   B) access to digital instructional videos/podcasts that address potential problems in deprescribing and provide possible solutions;~   C) checklist for identification of drug-related problems for pharmacists;~   D) tapering support tool to facilitate the selection of tapering schemes;~   E) divisibility list for PSA-PIM to support the implementation of tapering schemes;~   F) empowerment brochures for patients each focussing on one PSA-PIM subgroup~2. Interprofessional workshop and case conference for GPs and pharmacists~3. Pharmacy visit (brown bag/medication review) including patient empowerment~4. GP practice visit including shared decision making (SDM)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: The control intervention only comprises a pharmacy visit with brown bag review.
Study: NCT06173401

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single-fraction spine SRS
Description: Treatment Arm 1: Single-fraction spine SRS (22 Gy x 1)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Multi-fraction spine SRS
Description: Treatment Arm 2: Multi-fraction spine SRS (14 Gy x 2)
Study: NCT05475951

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biomarker measurement of pannexin-1 and gasdermin-D
Description: These biomarkers were measured in the placental and adipose tissues of the participants.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biomarker measurement of pannexin-1 and gasdermin-D
Description: These biomarkers were measured in the placental and adipose tissues of the participants.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biomarker measurement of pannexin-1 and gasdermin-D
Description: These biomarkers were measured in the placental and adipose tissues of the participants.
Study: NCT05967520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMKX000189
Description: JMKX000189 will be administered orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMKX000189
Description: JMKX000189 will be administered orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally once a day
Study: NCT05916690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Electrochemotherapy with bleomycin or cisplatin
Description: Combination of drug delivery platform (electroporation) and drug (bleomycin)
Study: NCT06316427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous CD7 CAR T-cell
Description: Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prior-HSCT donor-derived CD7 CAR T-cell
Description: Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from prior-HSCT donors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New donor-derived CD7 CAR T-cell
Description: Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from new donors.
Study: NCT06293157

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transpedicular spinal stabilization - carbon fibers-based implants
Description: Transpedicular stabilization with carbon fiber and PEEK-based implants in one of the two possible variants - first involves a large skin incision and separation of the back extensor muscles; second is associated with minimally invasive, which is percutaneous procedure that allows the stabilization with implants without the need to detach the muscles, using only a small skin incision.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transpedicular spinal stabilization - titanium implants
Description: Transpedicular stabilization with titanium implants in one of the two possible variants - first involves a large skin incision and separation of the back extensor muscles; second is associated with minimally invasive, which is percutaneous procedure that allows the stabilization with implants without the need to detach the muscles, using only a small skin incision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transpedicular spinal stabilization - titanium implants
Description: Transpedicular stabilization with titanium implants in one of the two possible variants - first involves a large skin incision and separation of the back extensor muscles; second is associated with minimally invasive, which is percutaneous procedure that allows the stabilization with implants without the need to detach the muscles, using only a small skin incision.

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Stereotactic body radiotherapy
Description: Spinal tumors will be treated with stereotactic body radiotherapy at a dose of 5x5 Gy (25 Gy in a total dose); either prior to or post-surgical treatment, accordingly the allocation to one of the study arms.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: Spinal tumors will be treated with stereotactic body radiotherapy at a dose of 5x5 Gy (25 Gy in a total dose); either prior to or post-surgical treatment, accordingly the allocation to one of the study arms.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic body radiotherapy
Description: Spinal tumors will be treated with stereotactic body radiotherapy at a dose of 5x5 Gy (25 Gy in a total dose); either prior to or post-surgical treatment, accordingly the allocation to one of the study arms.
Study: NCT05560893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relational Savoring Intervention
Description: Relational savoring (RS) involves recalling a time when one supported or comforted another person and doing so brought deep positive emotion (joy, satisfaction, love, or peace); these moments of connection in service of another are common among the CSPs who work for our community agency, but may go unnoticed in the face of the urgent stressors the COVID-19 pandemic has brought about. Prolonging and enhancing attention to these moments has the potential to both help CSPs restore regulation in the face of stress and to motivate CSPs to continue engaging in meaningful work that serves their communities.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Relational Savoring Intervention
Description: Relational savoring (RS) involves recalling a time when one supported or comforted another person and doing so brought deep positive emotion (joy, satisfaction, love, or peace); these moments of connection in service of another are common among the CSPs who work for our community agency, but may go unnoticed in the face of the urgent stressors the COVID-19 pandemic has brought about. Prolonging and enhancing attention to these moments has the potential to both help CSPs restore regulation in the face of stress and to motivate CSPs to continue engaging in meaningful work that serves their communities.
Study: NCT06258174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered orally.
Study: NCT05453292

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound guided radiofrequency ablation
Description: Patients will be first assessed by DFI-EUS and CE-EUS. Then. EUS guided RFA will be performed using the 19G electrode ablation needle connected to the Starmed radiofrequency generator (Taewong Medical, Seoul, South Korea). After EUS identification of the GIST, a place without interposing vessels will be found by the endosonographer. Puncture of the tumor will be performed directly with the ablation probe inserted through the working channel of the echoendoscope. Time - seconds will depend by the tumor dimension, localization, distance from vital structures (e.g., aorta) and EUS appearance (e.g., hyperechoic). Power will be set at no more than 30W. If the tumor is in contact with vital structures a 10mm safe margin will be kept from these to avoid thermal injury. Multiple applications can be performed in the same or separate session depending on the residual tumor tissue evaluated with DFI-EUSor CE-EUS immediately after procedure.
Study: NCT06446531

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet administered once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rybelsus Tablet
Description: Oral tablet started at a 3mg dose once daily and increased to 7mg once daily or maximum tolerable dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jardiance 25Mg Tablet
Description: Oral 25 mg Sodium-Glucose Co-Transporter (SGLT2) inhibitor administered once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral tablet started at a dose of 500mg with an increase of 500mg weekly up to a maximum dose of 2000mg (4 tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actos
Description: Oral tablet dosed at 15mg once daily
Study: NCT06104475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT scan
Description: A CT scan will be requested for every patient in addition to the chest X-ray
Study: NCT05149274

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWP14012 Tablet A
Description: DWP14012 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWP14012 Tablet A
Description: DWP14012 10mg
Study: NCT05149274

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWP14012 Tablet B
Description: DWP14012 40mg
Study: NCT05714189

Intervention type: OTHER
Group type: OTHER
Intervention: Low FODMAP diet
Description: The Low FODMAP diet is an avoidance diet and consist of three phases. In the first phase, all nutrients high in FODMAPs (high-FODMAPS) are eliminated from the daily diet over a period of 2 to 6 weeks to calm down the bowel. The second phase consists of the addition of FODMAP challenges. During this phase the patient continues the Low FODMAP diet, but will reintroduce one high-FODMAP nutrient once every three days to see whether exposure to this high-FODMAP causes IBS symptoms. When this is not the case, the patient can continue eating this high-FODMAP group in their daily diet. In the third and final phase, the diet is fully personalized. This personalization is based on whether the patient tolerated the high-FODMAP nutrient or not during the FODMAP challenges. Only when the high-FODMAP nutrient is not tolerated, it is advised to permanently remove it from the daily diet.

Intervention type: OTHER
Group type: OTHER
Intervention: Endometriosis diet
Description: The endometriosis diet The endometriosis diet is a patient experience based, avoidance diet developed by women diagnosed with endometriosis. Therefore no specific recommendations exist regarding the application of the endometriosis diet. With the endometriosis diet, women avoid nutrients they noticed provoked or aggravated their endometriosis-related symptoms such as red meat, coffee, sugar, lactose and soy.
Study: NCT06089811

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: Group 1 (prebiotic and placebo L-tryptophan): prebiotic (oligofructose, Orafti®P95, 20g/day) and placebo L-tryptophan (microcrystalline cellulose, 3g/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Tryptophan
Description: Group 2 (placebo prebiotic and L-tryptophan): L-tryptophan (3g/day) and placebo prebiotic (microcrystalline cellulose, 20g/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group 3 (placebo prebiotic and placebo L-tryptophan): placebo prebiotic (microcrystalline cellulose, 20g/day) and placebo L-tryptophan (microcrystalline cellulose, 3g/day).
Study: NCT05991154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Practice + JoyPop
Description: Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
Study: NCT05083247

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFIRINOX or Gemcitabine nab-paclitaxel
Description: oxaliplatin IV, irinotecan IV, leucovorin IV and 5-FU IV OR Gemcitabine IV Nab paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX or Gemcitabine nab-paclitaxel
Description: oxaliplatin IV, irinotecan IV, leucovorin IV and 5-FU IV OR Gemcitabine IV Nab paclitaxel

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Isotoxic High-Dose (iHD)-SBRT
Description: Radiation therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery
Study: NCT05970861

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Freeze-dried Mare Milk (Saumal)
Description: Freeze-dried Mare Milk (Saumal) is frequently reported for having therapeutic and dietary properties associated with specific chemical composition and certain physical properties of the product. It contains a total of about 40 biologically active components, the most important of them vitamins A, C, B1, B2, B6, and B12, amino acids, enzymes, and trace elements (low molecular weight peptides, lactalbumins, and globulins). Saumal will be administered to patients at a dose of 25 grams of dry powder per 200 ml of water, 2 times a day, 30 minutes before the meal, for 4 weeks.